Freya Pharma Solutions, a late clinical stage company focusing on the development of effective pharmaceutical therapies for women who have been diagnosed with Female Sexual Interest/Arousal Disorder (FSIAD).
Freya Pharma Solutions plans to conduct the pivotal Phase III clinical trial with its therapy Lybrido in 516 patients across Europe to confirm the efficacy of Lybrido in women suffering from female sexual interest/arousal disorder (FSIAD).
CR2O BV is leading the preparation, execution and reporting of this Phase III clinical trial.
Curious to learn more about CR2O’s full-service global CRO activities, or experience?
Please, contact Ellemieke von Mauw:
Ellemieke von Mauw
Director Clinical Programs | Business Development
T +31 (0)85 071 74 65 | M +31 (0)6 57 76 61 45 | E firstname.lastname@example.org